Dr Paul Wood is an Associate Investigator with the Hudson Monash Paediatric Precision Medicine program. Dr Wood is a paediatric oncologist with preclinical research experience who plans to expand his research interest into early phase paediatric cancer trials. He has devoted his translational research career to finding novel treatments for high-risk paediatric neuroblastoma. In particular, he has an interest in translational research and incorporating laboratory findings into patient care. Dr Wood has a current appointment as a consultant paediatric oncologist at Monash Health in Clayton, Victoria. He also has an honorary appointment at the Royal Children’s Hospital in Flemington, Victoria. In addition to his work in the acute cancer setting, Dr Wood is actively involved in the Long Term Follow-Up (LTFU) program looking at the long term impacts of cancer treatment on children. The remainder of Dr Wood’s work is dedicated to paediatric cancer research, with a particular emphasis on translational research.
Dr Wood completed a Master’s degree (Pharmacology) at Monash University in 1997. His thesis involved a Phase I clinical trial looking at altering the dosing schedule of aminoglycoside antibiotics to reduce toxicity. This was one of the earliest published early phase studies supporting the use of daily dosing of aminoglycosides. This experience is invaluable for a future career in early phase studies. Dr Wood is in the final stages of submitting a PhD investigating the role of the PI3K/mTOR pathway in neuroblastoma.
Waldeck K, Cullinane C, Ardley K, Shortt J, Martin B, Tothill RW, Li J, Johnstone RW, McArthur GA, Hicks RJ, Wood PJ (2016) Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-MYCN neuroblastoma mouse model. Int J Cancer 139:194-204.
Kong G, Hofman MS, Murray WK, Wilson S, Wood P, Downie P, Super L, Hogg A, Eu P, Hicks RJ (2015) Initial Experience With Gallium-68 DOTA-Octreotate PET/CT and Peptide Receptor Radionuclide Therapy for Pediatric Patients With Refractory Metastatic Neuroblastoma. J Pediatr Hematol Oncol 38:87-96.
Waldeck K, Cullinane C, Shortt J, Martin B, Ardley K, Tothill R, McArthur G, Wood PJ (2015) Prolonged survival of the TH-MYCN murine model of high-risk neuroblastoma, in response to the histone deacetylase inhibitor panobinostat, is the result of both apoptosis and differentiation. Cancer Res 75:abstract 5384.
Wood PJ, Strong R, McArthur GA, Michael M, Algar E, Muscat A, Rigby A, Ashley DM (2014) A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors. J Clin Oncol 35:abstract 10061.